Sadaf Sabzali, MD
Family Medicine · Allen, TXNPI 1033378732
Payments from drug & device makers
Across 294 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$616
- GSK$532
- AstraZeneca$451
- Abbott$292
- Novo Nordisk$237
- Kowa Pharmaceuticals America, Inc.$229
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,048100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 33 | $616 |
| GSK | 34 | $532 |
| AstraZeneca(2 entities) | 32 | $451 |
| Abbott | 16 | $292 |
| Novo Nordisk | 14 | $237 |
| Kowa Pharmaceuticals America, Inc. | 17 | $229 |
| AbbVie(2 entities) | 13 | $216 |
| Bayer | 10 | $207 |
| Merck | 13 | $200 |
| Lilly USA, LLC | 12 | $191 |
| Sanofi-aventis U.S. LLC | 12 | $190 |
| Amgen | 11 | $181 |
| Exact Sciences | 8 | $144 |
| Astellas Pharma US Inc | 6 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $127 |
| Dexcom, Inc. | 6 | $126 |
| Boehringer Ingelheim | 7 | $120 |
| Johnson & Johnson | 6 | $114 |
| Amarin Pharma, Inc. | 6 | $100 |
| Hologic Sales And Service, LLC | 1 | $79 |
| Novartis | 4 | $76 |
| Medtronic(2 entities) | 4 | $66 |
| Dynavax Technologies Corporation | 2 | $51 |
| VBI Vaccine (delaware) Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Optinose US, Inc. | 2 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Genentech USA, Inc. | 2 | $27 |
| Seqirus USA Inc | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Inogen, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Stryker | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
| Sanofi Pasteur Inc. | 1 | $11 |
How this compares
$5,054 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 67 | $83,721 |
| EliquisApixaban | 66 | $64,924 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $61,768 |
| JanuviaSitagliptin Phosphate | 47 | $61,257 |
| OzempicSemaglutide | 46 | $57,007 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 38 | $41,773 |
| MyrbetriqMirabegron | 27 | $33,742 |
| FarxigaDapagliflozin Propanediol | 17 | $27,041 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $24,815 |
| XareltoRivaroxaban | 27 | $22,903 |
| TradjentaLinagliptin | 22 | $21,347 |
| MounjaroTirzepatide | 15 | $19,826 |
| LinzessLinaclotide | 20 | $18,549 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $17,798 |
| VascepaIcosapent Ethyl | 30 | $16,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $120 | $105,06989 claims |
| MerckJanuvia, Janumet Xr | $200 | $103,03085 claims |
| PfizerEliquis | $616 | $64,92466 claims |
| GSKTrelegy Ellipta | $532 | $61,76871 claims |
| Novo NordiskOzempic | $237 | $57,00746 claims |
| Astellas Pharma US IncMyrbetriq | $136 | $33,74227 claims |
| AstraZenecaFarxiga | $451 | $27,04117 claims |
| Johnson & JohnsonXarelto | $114 | $22,90327 claims |
| AbbVieLinzess, Synthroid | $216 | $22,87377 claims |
| Lilly USA, LLCMounjaro | $191 | $19,82615 claims |
| Sanofi-aventis U.S. LLCAmbien | $190 | $7,45713 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $31 | $2,429277 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Allen
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.